Scarica l'app Stockscreener
113.75
77.43%
49.64
Dopo l'orario di chiusura:
113.72
-0.03
-0.03%
Arcellx Inc Borsa (ACLX) Ultime notizie
Gilead brings Arcellx fully under the fold for $7.8B - bioworld.com
Stock Movers: IBM, Door Dash, Arcellx - Bloomberg.com
Arcellx Advances Anito-cel as FDA Accepts BLA Filing - TipRanks
These Stocks Are Today’s Movers: Novo Nordisk, Lilly, PayPal, Arcellx, CrowdStrike, KKR, Strategy, and More - Barron's
Arcellx to Be Acquired by Gilead in $115-Per-Share Cash Deal Plus $5 CVR - TradingView
Arcellx Announces Game-Changing Development in Cancer Treatment - StocksToTrade
This Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It. - Barron's
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead - Wilson Sonsini
Recon: Gilead to purchase Arcellx for nearly $8B; Top CDC deputy abruptly resigns - Regulatory Affairs Professionals Society | RAPS
The M&A Class Action Firm Announces An Investigation of Arcellx, Inc. (NASDAQ: ACLX) - marketscreener.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Arcellx, Inc. (NASDAQ: ACLX) - PR Newswire
Gilead Raises $7.8 Billion To Acquire Arcellx And Expand Cancer Pipeline - Ventureburn
Evercore ISI cuts Arcellx stock rating to In Line on Gilead acquisition - Investing.com
Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer PipelineGEN - GEN - Genetic Engineering and Biotechnology News
Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma Drug in $7.8B Deal - MedCity News
Gilead to Acquire Arcellx in $7.8B Biotech Bet on Cancer Therapy - USA Herald
Biopharma firm Gilead to acquire Arcellx for $7.8 billion - The American Bazaar
Morgan Stanley reiterates Overweight on Gilead stock after Arcellx deal - Investing.com
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - AOL.com
Gilead buying homegrown cancer therapy company Arcellx for $7.8B - The Business Journals
Gilead: Downgrade To 'Hold' Rating Despite Arcellx Acquisition (NASDAQ:GILD) - Seeking Alpha
Top Midday Gainers - marketscreener.com
Here's why shares of Arcellx are up almost 80% today - MSN
Ropes, Wilson Sonsini Guide Gilead's $7.8B Arcellx Buy - Law360
Here's Why Shares of Arcellx Are Up Almost 80% Today - Investopedia
ACLX Downgraded by Needham: New Rating Update | ACLX Stock News - GuruFocus
Gilead Sciences Expands Oncology Portfolio with Arcellx Acquisition - GuruFocus
Novo Nordisk, Lilly, Arcellx, CrowdStrike, American Airlines, Strategy, and More Movers - Barron's
Arcellx Gains Spotlight with Innovative Presentation and Stock Sale Update - StocksToTrade
Midday Fly By: Trump ups worldwide tariff to 15%, Gilead buying Arcellx - TipRanks
Gilead to acquire Arcellx for $115 per share in cash at closing, or $7.8B - TipRanks
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Arcellx Stock (ACLX) Rockets on a Massive Deal with Gilead Sciences (GILD) - TipRanks
Gilead acquires CAR-T specialist Arcellx for $7.8bn - Pharmaceutical Technology
What Gilead Is Getting Through The Acquisition Of Arcellx - Seeking Alpha
Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders - Financial Times
Gilead to acquire CAR-T biotech Arcellx for $7.8bn - EMJ | Elevating the quality of healthcare globally
Gilead to buy Arcellx in $7.8bn deal to advance multiple myeloma treatment - BioXconomy
Arcellx’s Groundbreaking Research Spurs Optimism Amid Stock Fluctuations - timothysykes.com
Gilead buys Arcellx before it’s over the finish line | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J - Investor's Business Daily
Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion - marketscreener.com
Gilead Sciences Enters $7.8 Billion Definitive Agreement to Acquire Arcellx - Pharmaceutical Executive
Arcellx shares surge after Gilead announces $7.8B takeover deal - MSN
Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling - TechStock²
Arcellx Surges as Gilead’s $7.8B Offer Locks In a 68% Premium - Investing.com
Novo Nordisk, Lilly, Arcellx, American Airlines, Strategy, Domino’s, and More Movers - Barron's
Gilead to buy Arcellx for $7.8B, gaining full control of anito-cel - FirstWord Pharma
Why Did Arcellx (ACLX) Stock Surge 70%? $7.8B Buyout Deal - Tokenist
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Gilead to buy biotech Arcellx in deal worth up to $7.8 billion - MSN
Arcellx Stock Surges on Promising Cancer Treatment News - StocksToTrade
Why is Arcellx stock up 80% today? Gilead’s $7.8B answer - Invezz
Gilead Sciences To Acquire Arcellx In $7.8 Billion Deal To Strengthen Cell Therapy Portfolio - Pulse 2.0
Arcellx surges after Gilead agrees to acquire the CAR-T biotech in a deal worth up to $7.8B - Quiver Quantitative
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy - BioPharma Dive
Stock Movers: Gilead, Novo Nordisk, Domino's - Bloomberg.com
Novo’s next-gen obesity drug stumbles in Lilly comparison study - statnews.com
Truist cuts Arcellx stock rating on Gilead acquisition deal By Investing.com - Investing.com India
Spider silk strong enough to tow a car is headed for mass production in Vietnam - Stock Titan
Gilead to Buy US Biotech Arcellx for Up to $7.8 Billion - Bloomberg.com
Sector Update: Health Care Stocks Mixed Premarket Monday - marketscreener.com
Gilead Sciences to buy Arcellx to maximize long-term potential of anito-cel - MLex
Morning Movers: Arcellx skyrockets following pact to be acquired - TipRanks
Gilead Sciences Acquires Arcellx, for $7.8 Billion - FinSMEs
Gilead Sciences to snap up Arcellx in near $8bn deal - Sharecast.com
Why Arcellx Stock Is Dropping Despite Buyout Deal - TipRanks
2.25%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):